Early intravenous administration of nutritional support (IVANS) in metastatic gastric cancer patients at nutritional risk, undergoing first-line chemotherapy: study protocol of a pragmatic, randomized, multicenter, clinical trial

Riccardo Caccialanza, Emanuele Cereda, Catherine Klersy, Silvia Brugnatelli, Valeria Borioli, Alessandra Ferrari, Marilisa Caraccia, Federica Lobascio, Anna Pagani, Sara Delfanti, Giuseppe Aprile, Michele Reni, Lorenza Rimassa, Davide Melisi, Stefano Cascinu, Luca Battistini, Francesca Candiloro and Paolo Pedrazzoli

Abstract

Background: Malnutrition is common in cancer patients, particularly in those affected by gastrointestinal malignancies, and negatively affects treatment tolerance, survival, functional status, and quality of life (QoL). Nutritional support, including supplemental parenteral nutrition (SPN), has been recommended at the earliest opportunity in malnourished cancer patients. The limited available evidence on the efficacy of SPN in gastrointestinal cancer patients is positive, particularly with regards to QoL, body composition, and energy intake, but the evidence on survival is still scanty. Furthermore, studies regarding the early administration of SPN in combination with nutritional counseling from the beginning of first-line chemotherapy (CT) are lacking. We hypothesize that early systematic SPN in combination with nutritional counseling (NC), compared with NC alone, can benefit patients with previously untreated metastatic gastric cancer at nutritional risk undergoing first-line CT.

Methods: The aim of this pragmatic, multicenter, randomized (1:1), parallel-group, open-label, controlled clinical trial is to evaluate the efficacy in terms of survival, weight maintenance, body composition, QoL and feasibility of cancer therapy of early systematic SNP. This is in combination with NC, compared with NC alone, in treatment-naive metastatic gastric cancer patients at nutritional risk undergoing first-line CT.

Discussion: Malnutrition in oncology remains an overlooked problem. Although the importance of SPN in gastrointestinal cancer patients has been acknowledged, no studies have yet evaluated the efficacy of early SPN in metastatic gastric patients undergoing CT. The present study, which guarantees the early provision of nutritional assessment and support to all the enrolled patients in accordance with the recent guidelines and recommendations, could represent one of the first proofs of the clinical effectiveness of early intensive nutritional support in cancer patients undergoing CT. This study could stimulate further large randomized trials in different cancer types, potentially resulting in the improvement of supportive care quality.

Trial registration: This study is registered on ClinicalTrials.gov: NCT03949907.

Keywords: body composition, gastric cancer, malnutrition, nutritional counseling, supplemental parenteral nutrition, survival

Received: 26 June 2019; revised manuscript accepted: 29 October 2019.
Background

Malnutrition is common in cancer patients, particularly in those affected by gastrointestinal malignancies, and negatively affects treatment tolerance, survival, functional status, and quality of life (QoL). It is known that nutritional status tends to worsen over the course of the illness and that inadequate nutritional support may negatively affect not only nutrition and function, but also prognosis in cancer patients. In recent years, there has been growing evidence that increased treatment toxicity and poorer prognosis are associated with lean body mass (LBM) loss that leads to sarcopenia in the most common cancer types and, consequently, to impaired functional status and QoL. Therefore, more proactive or even intensive nutritional support should be considered in this patient population.

The most recently available guidelines recommend the use of supplemental parenteral nutrition (SPN) during nonsurgical therapy if cancer patients are malnourished, hypophagic, or affected by iatrogenic gastrointestinal complications, and if enteral nutrition is not feasible. A recent task force of the American Society for Parenteral and Enteral Nutrition, however, has recommended artificial nutrition, including SPN, at the earliest opportunity in malnourished patients. The limited available evidence on the efficacy of SPN in gastrointestinal cancer patients is positive, in particular with regards to QoL, body composition, and energy intake, but the evidence on survival is still scant. Furthermore, studies on the effect of early administration of SPN in combination with nutritional counseling (NC) from the start of first-line chemotherapy (CT), are lacking.

The aim of this pragmatic, randomized, multicenter clinical trial (ClinicalTrials.gov identifier: NCT03949907) is to evaluate the efficacy in terms of survival, weight maintenance, body composition, QoL, and feasibility of cancer therapy, of early systematic SPN. This is in combination with NC, compared with NC alone, in patients with previously untreated metastatic gastric cancer at nutritional risk undergoing first-line CT.

Methods/design

Standard protocol approval, registration, and patient consent

This study will be conducted in accordance with good clinical practice and with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. The study protocol was approved by the Fondazione IRCCS Policlinico San Matteo (Pavia, Italy) Ethics Committee (19 April 2019; version 1) and registered on ClinicalTrials.gov (identifier: NCT03949907). Written informed consent will be obtained from every patient entering the study by the medical personnel of the participating institutions and it will be made clear that patients may withdraw from the study at any time without providing a reason and without affecting their current or future care. General practitioners will be kept informed on the study’s progress.

Design

This study will be a pragmatic, multicenter, randomized (1:1), parallel-group, open-label, controlled clinical trial. Allocation of patients, fulfilling inclusion criteria to the intervention groups, will be performed at the baseline visit according to a computer-generated randomization list. Concealment will be attained by using a web-based randomization.

Subjects

Consecutive adult patients (18 years old or more) with a histologically confirmed diagnosis of metastatic gastric and gastroesophageal junction cancer will be considered eligible in the presence of: the indication of a first-line CT with a combination of two drugs including platinum derivatives (plus Trastuzumab if HER2 positive) to be used according to the investigator’s choice within the framework of good clinical practice and in agreement with current Italian Association of Medical Oncology guidelines; a measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST 1.1); a nutritional risk (Nutritional Risk Screening (NRS) 2002 score of three or more); a permanent venous access (port-a-cath, Groshong, Peripherally Inserted Central Catheter) available; an Eastern Cooperative Oncology Group performance status of two or less. Patients will be excluded in cases of: an indication to complete artificial nutrition support (totally compromised spontaneous food intake); a contraindication to parenteral nutrition (PN; e.g. abnormal glucose and electrolytes control, hypertriglyceridemia, impaired hemodynamic control, or relevant fluid retention); the presence of jejunostomy for nutritional purposes; an ongoing home artificial nutrition; an unfeasible home parenteral nutrition.
(HPN) for social/familial reasons, including the absence of caregivers.

Assessments
In addition to general demographic and clinical data (tumor site, histology, and stage, as well as scheduled anticancer treatment), the following assessments will be performed:

Anthropometry. Body weight (to the nearest 0.1 kg), history of 6-month and 1-month previous unintentional weight loss (WL), height (to the nearest 0.5 cm), and body mass index (BMI) will be recorded.

Nutritional requirements. Energy requirements will be estimated by multiplying the resting energy expenditure (calculated using the Harris–Benedict equation) by a correction factor of 1.5 [in obese patients (BMI > 30 kg/m²) ideal body weight at a BMI = 23 kg/m² will be used in the equation], while protein requirements will set to 1.5 g/kg of actual body weight (or ideal body weight in obese patients).³,⁴,²⁷,²⁸

Calorie and protein intakes. Calorie and protein intakes from food sources will be estimated at all treatment visits using the 24-h dietary recall method.²⁸–³⁰ Total intakes throughout the study will be calculated taking into consideration the SPN prescriptions and will be considered achieved when total energy and protein requirements attain ≥90% of estimated requirements and ≥1.5 g/kg/day, respectively.

Nutritional risk. This will be assessed at the screening visit using the NRS-2002 screening tool,²⁵ which is based on the information collected on BMI, 6-month unintentional WL and food intake, as well as on diagnosis and age.

Biochemistry. In addition to standard tests usually performed to monitor CT toxicity, a series of assessments will be considered to monitor potential PN-associated metabolic complications. Accordingly, the following parameters will be evaluated at scheduled visits: glycemia, sodium, potassium, magnesium, calcium, phosphorus, triglycerides, creatinine, urea, liver serum enzymes (aspartate aminotransferase, alanine aminotransferase, gamma glutamyltransferase), total bilirubin, prealbumin, C-reactive protein, total blood count, blood iron, ferritin, vitamin B12, and folates.

Body composition. Whole-body composition will be investigated using the Nutrilab bioimpedance vector assay (BIVA; Akern/RJL). Specifically, resistance and reactance will be measured by calculating phase angle (PhA), standardized PhA (SPA), and hydration index.³¹,³²

Muscle mass at lumbar level. The estimation of muscle mass will be performed using computed tomography: muscle area will be quantified on scans at L3,³³ collected at baseline disease staging and subsequent reassessments scheduled by the oncologists for the evaluation of the response to CT.

Muscle strength. Muscle strength [handgrip (HG)] will be measured using a digital hand dynamometer (DynEx™, Akern/MD Systems).³²

Quality of life. This will be investigated using the European Organization for Research and Treatment of Cancer core quality of life questionnaire (EORTC QLQ-C30, version 3.0) and the dietician will provide instructions for the correct compilation.³⁴

Symptoms. Patients will be asked about the presence or onset of symptoms potentially influencing food intake, including anorexia, dysphagia, odynophagia, dysgeusia, nausea, vomiting, and diarrhea.

Adverse complications and events. All adverse complications and events attributable to nutritional interventions (water retention and infectious, cardiac, renal, respiratory, and metabolic complications), including unplanned hospitalizations and their duration, will be recorded.

Immunologic profile. To address this exploratory endpoint in a subgroup of patients [N = 30 (15 consecutive patients in each randomization group)], we will integrate measurements obtained using multiple tools, with the aim of analyzing different cell subsets, their functionality, and soluble molecules in the peripheral blood. The analysis will be conducted by the Neuroimmunology Unit of the Santa Lucia Foundation IRCCS (Rome, Italy). Accordingly, blood samples (5 vials with a total volume of 40 ml) will be collected and derived serum and plasma will be analyzed using the Luminex technology for the assessment of 30 soluble factors associated with the inflammatory and immunoregulatory states (CCL2/MCP-1; CCL3/MIP-1 alpha; CCL4/MIP-1 beta; CCL5/...
RANTES; CCL11/Eotaxin; CCL20/MIP-3 alpha; CD25/IL-2 receptor alpha; CX3CL1/Fractalkine; CXCL9/MIG; CXCL10/IP-10; Fas; Fas Ligand; GM-CSF; Granzyme B; IFN-gamma; IL-2; IL-3; IL-4; IL-5; IL-6; IL-9; IL-10; IL-12 p70; IL-13; IL-15; IL-17A; IL-17F; IL-22; IL-27; TNF-alpha) together with the patients’ cellular immunologic profiles using 18-color flow cytometry.35,36 The following antibodies will be used: KLRG, CXCR3, CD95, CD39, CD25, CD3, CD45RA, CD123, CD38, IL-1β, IL-12, LAIR, γδ, PD-1, Perforin, Granzyme A, Granzyme B, HLA-DR, GM-CSF, IL-2, INFγ, IL-14, TNFα, CD95, CD56, CD45RA, CCR6, CD4, CD3, CD57, CD27, CD19, CD23, CD69, CD80, CD8; CD158 b1/b2i, CD158a, CD16, NKG2A, CD56, CD4, CD127, CD161, CD11c, CD8, IL-10, IL-17, IL-6, HLA-DR, CD14, Foxp3, CD19, TNFα, Vδ2, IFNα, CD49d, CD83, CD86, live/dead.

A summary of assessments and related endpoints that will be investigated during the study, is provided in Table 1.

**Treatment**

Patients will be randomized to the following intervention groups:

- NC in combination with systematic early supplemental HPN since diagnosis (SPN group).
- NC alone (NC group).

NC consists of a personalized dietary prescription (including sample meal plans and recipe suggestions) tailored on personal eating patterns and food preferences, in order to achieve estimated protein-calorie requirements and taking into account chewing and swallowing abilities.28 Regular consultation with a registered diettian will take place every 10 days by means of face-to-face interviews (at scheduled follow-up visits) and telephone interviews (planned between CT cycles and as required by the patient). In the presence of a significant reduction in food intake, the use of oral nutritional supplements will be also considered.

Supplemental HPN will be prescribed, provided daily, and adjusted throughout the study (approximately every 10 days, until the end of the scheduled first-line CT) depending on the biochemical parameters, the estimated protein-calorie oral intakes (in order to satisfy estimated requirements) and any potential related complications. Specifically, calorie and protein targets should not exceed 40 kcal/kg and 2 g/kg of body weight (real or ideal according to BMI), respectively.32 HPN will be infused mainly during night hours using multichamber bags containing olive oil-based lipid emulsions when not contraindicated (triglycerides levels >300 mg/dl). Supplemental HPN will be continued at least up to the end of first-line CT. Afterwards, it will be progressively reduced in cases showing complete recovery of usual body weight and a protein-calorie food intake ≥75% of the estimated requirements.

Where body WL exceeds 10% of the weight recorded at enrollment, patients allocated to the NC group will exit the study. They will be treated according to current supportive guidelines, including HPN and followed-up for vital status.

**Endpoints**

The primary outcome will be a composite of 1-year overall survival (OS) or the absence of unintentional WL ≥10% of weight recorded at enrollment. Specifically, vital status will be ascertained by means of active follow-up (in-office visits, inquiries by telephone or mail to participants or proxy respondents and linkage to municipal registries), while WL will be regularly documented at scheduled visits.

The following secondary endpoints will be also evaluated: 1-year OS; first-line treatment-related moderate–severe adverse events (grade three or greater) according to Common Terminology Criteria for Adverse Events (v4.0);37 progression-free survival (PFS) at 12 months; rate of patients with progressive disease receiving second-line CT; total dose (%) of first-line CT administered compared with the treatment plan; objective response rate to first-line CT using RECIST criteria;24 change in body weight at 12 months; change in handgrip strength at 12 months; change in L3 muscle mass at 4 months and, if feasible, at 12 months evaluated with computed tomography; change in PhA and SPA at 4 months and 12 months evaluated by BIVA; rate of unplanned hospitalizations at 12 months; change in EORTC QLQ-C30 score at 4 months and 12 months.

The safety of SPN will be evaluated by monitoring the incidence of catheter-related bloodstream infections and the occurrence of abnormalities in
biochemical parameters (metabolic complications) and all related side effects.

Finally, the levels of soluble effectors and immunoregulatory cells at 1 week and 1 month from the start of CT will be assessed as an exploratory endpoint.

| Table 1. Summary of scheduled assessments. |
|------------------------------------------|
| **Procedures and assessments** | **Visit 1** | **Visit 2** | **Visit 3** | **Visit 4** | **Visit 5** | **Visit 6** | **Visit 7** | **Visit 8** |
|------------------------------------------|
| Informed consent form | X | | | | | | | |
| Demographic and general clinic data collection | X | | | | | | | |
| Cancer staging | X | | | | | | | |
| CT scheduling | X | | | | | | | |
| Inclusion/exclusion criteria | X | | | | | | | |
| Randomization | X | | | | | | | |
| Anthropometry | X | X | X | X | X | X | X | X |
| Calorie and protein requirements | X | X | X | X | X | X | X | X |
| Calorie and protein intake | X | X | X | X | X | X | X | X |
| Symptoms | X | X | X | X | X | X | X | X |
| Biochemistry | X | X | X | X | X | X | X | X |
| Immunologic profile* | X | | | | | | | |
| Body composition by bioelectric impedance | X | | X | | X | | | |
| Muscle mass by computed tomography | X | | | | | | | |
| Muscle strength | X | X | | | | | | |
| Total CT received | | | | | | | | X |
| CT toxicity | X | X | X | X | X | X | X | X |
| Quality of life (EORTC QLQ-C30) | X | | | | | | | X |
| Adverse event (safety) | X | X | X | X | X | X | X | X |
| Unplanned hospitalization | | | | | | | | X |
| HPN compliance* | X | X | X | X | X | X | X | X |
| Survival status | X | X | X | X | X | X | X | X |

CT, chemotherapy; EORTC QLQ-C30, European Organization for Research and Treatment of Cancer core quality of life questionnaire version 3.0; HPN, home parenteral nutrition. *To be assessed only in patients randomized to early HPN.

**Benefit for participants**

All participants will be provided with early nutritional assessment and support. The participants nutritional status will be regularly monitored and their nutritional support will be optimized according to treatment tolerance and possible side-effects.
This study may lead to significant improvements in nutritional care, which will prevent or ameliorate the effect of CT in gastric cancer patients.

Potential risks and burdens for research participants
The participants will have a permanent venous access already available. SPN will be tailored according to oral intake and regularly monitored. Nevertheless, SPN may cause discomfort or expose the patients to an increased risk of PN-associated complications that may also depend on the efficacy of the training provided to patients and caregivers with regards to HPN management. Available data, however, shows that HPN can be safely provided by caregivers and cancer patients.38,39

Dissemination
Results of the study will be presented at local, national, and international medical meetings. The findings of the study will be published in peer-reviewed medical/scientific journals and made open access on acceptance. If appropriate, the results of the study will be disseminated by press releases by the Fondazione IRCCS Policlinico San Matteo. Information may also be disseminated to the general public via public engagement and community outreach programs.

Statistics
In the absence of previous studies with a similar design, the calculation of the sample size is based only on the survival component of the primary endpoint. It was performed with the Stata 15.1 software (StataCorp, College Station, TX, USA). According to preliminary data available in the literature, 12-month survival is expected to be around 45% in this type of patient. It is assumed that, based on data on mortality due to malnutrition in advanced cancer patients, NC alone can increase the 12-month survival rate to 50%. Considering a study power of 80%, an alpha error at two tails of 5%, an expected survival in the experimental arm (NC + SPN) of 70%, it will be necessary to enroll about 192 patients (96 per arm) to observe 77 deaths. When this number of events is reached, the study will be discontinued. Estimation of the sample size makes use of the two-sample comparison of survivor functions using the log-rank test (Freedman method).

The analysis will be performed with the Stata 15.1 software (StataCorp, College Station, TX, USA) or subsequent versions. All tests will be 2-sided. A $p$ value <0.05 will be considered statistically significant. For post-hoc comparisons and subgroup analyses the Bonferroni correction will be used.

Analysis sets. Patients who have signed informed consent and have carried out at least one planned check will be considered for analysis. The main analysis will be carried out according to the intention to treat principle: the patients of the analysis set will be analyzed (mITT) according to the treatment to which they were randomized, regardless of the treatment actually undergone. A per protocol analysis will also be performed, considering the treatment actually administered, in the absence of major deviations (including, but not restricted to, cross-over to the other arm, early drop out before second assessment, inappropriate SPN prescription and/or management, etc.) from the protocol. These will be identified before the database lock.

Primary endpoint analysis. OS will be compared using the log-rank test. The relative risk and its 95% confidence interval (CI) will be derived from a Cox model. A multivariable secondary analysis of the primary endpoint will also be performed while adjusting for age, gender, BMI, PhA, and hydration index, as confounding factors at recruitment.

In addition, the statistical analysis plan will detail some prespecified subgroup analyses, according to the site of the neoplasm, the stage of neoplasm, HER2 expression, the presence of a gastrectomy and the total number of CT cycles received during the observation period.

Secondary endpoints will be analyzed as follows.

- PFS will be compared among groups, as described for OS.
- The percentage of patients requiring second-line CT will be compared with a logistical model, with odds ratio (OR) and 95% CI calculations.
- The percentage of CT dose administered compared with the planned 4-month dosage will be compared using Student $t$ tests for independent samples (or its nonparametric analog).
- The percentage of patients with dose-limiting toxicity will be compared with a logistic model, with OR and 95% CI calculation.
- The percentage of patients with responses to CT will be compared with a logistic model, with OR and 95% CI calculation.
- The variation over time of secondary efficacy and QoL measures will be compared between the two treatment groups by means of a generalized logistic or linear regression model for repeated measurements (according to the type of dichotomous or continuous endpoint). The test on the interaction time \( \times \) treatment term will verify the effectiveness of the latter.
- For safety, descriptive statistics will be calculated separately for each treatment group.
- The following dichotomous endpoints will be considered: dose-limiting toxicity, response to CT, and catheter-related bloodstream infections.
- The following continuous endpoints will be considered: weight variations, BMI, PhA, SPA, hydration index, LBM, HG, biochemical parameters, and EORTC QLQ-C30 score.
- Definition and drop-outs management: patients who have left the study (drop-out) before 4 months will not be included in the mITT analysis population. Therefore, a sensitivity analysis will be performed with multiple imputations of missing data for the primary endpoint. Patients leaving the study after 4 months will be censored on the date of leaving for primary endpoint analysis. Every effort will be made to recover the mortality rate.
- Patients who voluntarily discontinue the study or are lost at follow-up will be considered drop-outs.

**Study organization**

The Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, is responsible for the project management of the trial. The study was planned by the Clinical Nutrition and Dietetics Unit, the Medical Oncology Unit, the Biometry and Clinical Epidemiology Service of the Fondazione IRCCS Policlinico San Matteo, and the board of oncologists from other institutions listed as coauthors. Periodic board meetings will be scheduled (approximately every 6 months) in order to harmonize study procedures and to monitor and share the study progression.

**Participating institutes**

Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; San Bortolo General Hospital, Vicenza, Italy; Azienda Socio-Sanitaria Territoriale Fatebenefratelli Sacco, Milan, Italy; Veneto Institute of Oncology-IRCCS, Padua, Italy; Azienda Socio-Sanitaria Territoriale of Melegnano e della Martesana, Italy, Milan; University Hospital of Modena, Modena, Italy; IRCCS San Raffaele Scientific Institute, Milan, Italy; Azienda Socio-Sanitaria Territoriale of Pavia, Pavia, Italy; Humanitas Clinical and Research Center IRCCS, Rozzano (Milan), Italy; University Hospital of Verona, Verona, Italy; Neuroimmunology Unit, Santa Lucia Foundation IRCCS, Rome, Italy.

Further institutes will be invited. Researchers and physicians who may be interested in participating in the trial should contact the corresponding author for detailed information.

The study protocol will be submitted to each participating institute’s Ethics Committee for approval. Any possible important protocol modifications will be communicated and submitted to the same committees.

**Discussion**

Malnutrition in oncology still represents an overlooked problem that negatively affects clinical outcomes.\(^6,40,41\) This is particularly marked in gastrointestinal cancer patients.\(^5,9,13,42–45\) The evidence supporting the efficacy of nutritional support in patients affected by gastric cancer is promising, but still scant and mainly focused on the perioperative/postoperative period.\(^46–50\)

Although the importance of PN support in gastrointestinal cancer patients has been acknowledged,\(^51\) there are still no studies evaluating the efficacy of SPN in metastatic patients receiving first-line CT. Evidence suggests a beneficial effect of early and tightly controlled nutritional support in the presence of malnutrition.\(^52,53\) The present study ensures the early provision of nutritional assessment and support to all the enrolled patients, in accordance with recent guidelines and recommendations,\(^3,4,15\) and would help clarify the most appropriate and beneficial nutritional care strategy for metastatic gastric cancer patients.

Toxicity frequently requires the prolongation or reduction of planned systemic treatments, resulting in reduced response rates and poor
prognosis. Therefore, nutritional support from diagnosis, aimed at satisfying estimated energy requirements in patients at nutritional risk, may enable not only the maintenance/ improvement of nutritional status and QoL, but may also have a positive and decisive effect on adherence to anticancer treatment and the related curative intent.

With the present trial, we aim to verify the hypothesis that early SPN from diagnosis in metastatic gastric patients at nutritional risk undergoing first-line CT and receiving NC as standard of care not only improves nutritional status, body composition, functional status, and QoL, but also increases tolerance to CT by maintaining weight, thereby improving OS.

NC itself has been proven effective in improving protein-calorie intake and QoL in malnourished cancer patients, and was recommended for all gastrointestinal cancer patients undergoing anticancer treatment more than 10 years ago. However, data on its efficacy on OS and other primary clinical endpoints in gastric cancer patients are lacking.

Positive results from this trial would stimulate further large randomized trials, also in other cancer types, potentially resulting in the improvement of supportive care quality for the studied patient populations, and in the expansion of the number of patients who may benefit from HPN. In this context, the management of HPN will always require the fulfillment of adequate quality standards and the attentive consideration of any possible ethical issue regarding prescriptions’ suitability and treatment interruption.

Finally, the immune response is emerging as a key factor affecting the efficacy of several anticancer treatments. Olive oil-enriched lipid emulsions were shown to have promising and intriguing effects on immune function. To date, the impact of PN, particularly of olive oil-based lipid emulsions, on the immunological profile of cancer patients undergoing CT has not been investigated. Therefore, we will also evaluate the immunological profile and how it changes during nutritional support in gastric cancer patients receiving first-line CT.

This approach may help to clarify the interactions between the immune system and olive oil-enriched PN. This new area of research could lead to the discovery of new molecular mechanisms regulating the immune system during CT and potentially to the development of new therapeutic strategies aimed at enhancing the efficacy of anticancer treatments.

A possible practical critical aspect of the study could be the standardization of nutritional support interventions. To achieve this, however, participating centers would need physicians and dietitians skilled in clinical nutrition and who are following standardized protocols.

Acknowledgment
The authors are grateful to Dr. Paul Baines for assistance in editing the manuscript.

Author’s Note
Lorenza Rimassa is also affiliated with Department of Biomedical Sciences, Humanitas University, Pieve Emanuele Milan, Italy.

Author contributions
RC, EC, CK, SB, SD, GA, MR, LR, SC, LB, DM, and PP developed the study concept and protocol. CK, VB, MC, FL, AF, and AP assisted in further development of the protocol. RC, EC, CK, SB, SD, GA, MR, LR, DM, SC, and PP drafted the clinical study protocol, funding, and ethics application. RC, EC, CK, SB, GA, MR, LR, SC, LB, FC, and PP drafted the manuscript. All authors contributed and approved the final manuscript. RC and PP act as guarantors of the study.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: the study was funded by the Fondazione IRCCS Policlinico San Matteo, Pavia, Italy and by an unrestricted grant from Baxter Healthcare Corporation.

Conflict of interest statement
RC has received research funding from Baxter Healthcare Corporation. RC and PP have served as consultants and/or on advisory panels for Baxter Healthcare Corporation. LB has served as scientific lecturer and/or on advisory panels for Baxter Healthcare Corporation, Roche, Merck, Teva, Genzyme and Novartis. RC and PP have participated in speakers’ bureaus for Baxter Healthcare Corporation. RC and EC have participated in speakers’ bureaus for Akern s.r.l.
Availability of data and material
The datasets generated and/or analyzed during the current study are not publicly available owing to the Italian privacy law but are available from the corresponding author on reasonable request.

Consent for publication
All authors have approved the submission of this manuscript for publication. No restriction of future publication of data is made by any of the study partners.

Ethics approval and consent to participate
This study has been reviewed as ID 20190028466 by the Institutional Ethics Committee of the Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, who gave a favorable opinion (19/04/2019; version 1).

The study sponsor is Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. This study is registered on ClinicalTrials.gov Identifier: NCT03949907.

All individuals recruited to the study will participate freely and after fully informed consent.

ORCID iDs
Riccardo Caccialanza https://orcid.org/0000-0002-9379-3569
Lorenza Rimassa https://orcid.org/0000-0001-9957-3615

References
1. Hébuterne X, Lemarié E, Michallet, et al. Prevalence of malnutrition and current use of nutrition support in patients with cancer. J Parenter Enteral Nutr 2014; 38: 196–204.
2. Van Cutsem E and Arends J. The causes and consequences of cancer-associated malnutrition. Eur J Oncol Nurs 2005; 9: S51–S63.
3. Arends J, Bachmann P, Baracos V, et al. ESPEN guidelines on nutrition in cancer patients. Clin Nutr 2017; 36: 11–48.
4. Caccialanza R, Pedrazzoli P, Cereda E, et al. Nutritional support in cancer patients: a position paper from the Italian Society of Medical Oncology (AIOM) and the Italian Society of Artificial Nutrition and Metabolism (SINPE). J Cancer 2016; 7: 131–135.
5. Klute KA, Brouwer J, Jhaever M, et al. Chemotherapy dose intensity predicted by baseline nutrition assessment in gastrointestinal malignancies: a multicentre analysis. Eur J Cancer 2016; 63: 189–200.
6. Kaikani W and Bachmann P. Consequences of a comorbidity often neglected in oncology: malnutrition. Bull Cancer 2009; 96: 659–664.
7. Norman K, Pichard C, Lochs H, et al. Prognostic impact of disease-related malnutrition. Clin Nutr 2008; 27: 5–15.
8. Prado CM, Antoun S, Sawyer MB, et al. Two faces of drug therapy in cancer: drug-related lean tissue loss and its adverse consequences to survival and toxicity. Curr Opin Clin Nutr Metab Care 2011; 14: 250–254.
9. Aoyama T, Kawabe T, Fujikawa H, et al. Loss of lean body mass as an independent risk factor for continuation of S-1 adjuvant chemotherapy for gastric cancer. Ann Surg Oncol 2015; 22: 2560–2566.
10. Jung HW, Kim JW, Kim JY, et al. Effect of muscle mass on toxicity and survival in patients with colon cancer undergoing adjuvant chemotherapy. Support Care Cancer 2015; 23: 687–694.
11. Nipp RD, Fuchs G, El-Jawahri A, et al. Sarcopenia is associated with quality of life and depression in patients with advanced cancer. Oncologist 2018; 23: 97–104.
12. Guinan EM, Doyle SL, Bennett AE, et al. Sarcopenia during neoadjuvant therapy for oesophageal cancer: characterising the impact on muscle strength and physical performance. Support Care Cancer 2018; 26: 1569–1576.
13. Ongaro E, Buoro V, Cinausero M, et al. Sarcopenia in gastric cancer: when the loss costs too much. Gastric Cancer 2017; 20: 563–572.
14. Russell MK and Wischmeyer P. Supplemental parenteral nutrition: review of the literature and current nutrition guidelines. Nutr Clin Pract 2018; 33: 359–369.
15. Worthington P, Balint J, Bechtold M, et al. When is parenteral nutrition appropriate? J Parenter Enteral Nutr 2017; 41: 324–377.
16. Cotogni P, De Carli L, Passera R, et al. Longitudinal study of quality of life in advanced cancer patients on home parenteral nutrition. Cancer Med 2017; 6: 1799–1806.
17. Oblining SR, Wilson BV, Pfeiffer P, et al. Home parenteral nutrition increases fat free mass in patients with incurable gastrointestinal cancer. Results of a randomized controlled trial. Clin Nutr 2019; 38: 182–190.
18. Cotogni P, Monge T, Fadda M, et al. Bioelectrical impedance analysis for monitoring
cancer patients receiving chemotherapy and home parenteral nutrition. BMC Cancer 2018; 18: 990.

19. Bozzetti F. Nutritional interventions in elderly gastrointestinal cancer patients: the evidence from randomized controlled trials. Support Care Cancer 2019; 27: 721–727.

20. Pelzer U, Arnold D, Gövecin M, et al. Parenteral nutrition support for patients with pancreatic cancer. Results of a phase II study. BMC Cancer 2010; 10: 86.

21. Richter E, Denecke A, Klapdor S, et al. Parenteral nutrition support for patients with pancreatic cancer—improvement of the nutritional status and the therapeutic outcome. Anticancer Res 2012; 32: 2111–2118.

22. Wu W, Zhong M, Zhu DM, et al. Effect of early full-calorie nutrition support following esophagectomy: a randomized controlled trial. J Parenter Enteral Nutr 2017; 41: 1146–1154.

23. Associazione Italiana di Oncologia Medica. Neoplasie dello stomaco e della giunzione esofago-gastrica. Linee guida 2018, https://www.aiom.it/linee-guida-aiom-2018-neoplasie-dello-stomaco-e-della-giunzione-esofago-gastroica/

24. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228–247.

25. Kondrup J, Rasmussen HH, Hamberg O, et al. Ad Hoc ESPEN Working Group. Nutritional risk screening (NRS 2002): a new method based on an analysis of controlled clinical trials. Clin Nutr 2003; 22: 321–336.

26. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649–655.

27. Harris JA and Benedict FG. A biometric study of human basal metabolism. Proc Nail Acad Sci USA 1918; 4: 370–373.

28. Cereda E, Cappello S, Colombo S, et al. Nutritional counseling with or without systematic use of oral nutritional supplements in head and neck cancer patients undergoing radiotherapy. Radiother Oncol 2018; 126: 81–88.

29. Istituto Nazionale di Ricerca per gli Alimenti e la Nutrizione (I.N.R.A.N.). Tabelle di Composizione degli Alimenti. Aggiornamento 2000. EDRA Medical Publishing & New Media, 2000.

30. Istituto Scotti Bassani. Atlante Ragionato di Alimentazione. Istituto Scotti Bassani per la ricerca e l’informazione scientifica e nutrizionale, Milano, 1989.

31. Norman K, Stobäus N, Pirlich M, et al. Bioelectrical phase angle and impedance vector analysis—clinical relevance and applicability of impedance parameters. Clin Nutr 2012; 31: 854–861.

32. Caccialanza R, Cereda E, Caraccia M, et al. Early 7-day supplemental parenteral nutrition improves body composition and muscle strength in hypophagic cancer patients at nutritional risk. Support Care Cancer 2019; 27: 2497–2506.

33. Lemos T and Gallagher D. Current body composition measurement techniques. Curr Opin Endocrinol Diabetes Obes 2017; 24: 310–314.

34. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365–376.

35. Angelini DF, Ottone T, Guerrera G, et al. A leukemia-associated CD34/CD123/CD25/CD99+ immunophenotype identifies FLT3-mutated clones in acute myeloid leukemia. Clin Cancer Res 2015; 21: 3977–3985.

36. Ottone T, Alfonso V, Iaccarino L, et al. Longitudinal detection of DNMT3A(R882H) transcripts in patients with acute myeloid leukemia. Am J Hematol 2018; 93: E120–E123.

37. National Cancer Institute Common Toxicology Criteria. Common Terminology Criteria for Adverse Events [CTCAE] V4.03, 2010.

38. Cotogni P, Barbero C, Garrino C, et al. Peripherally inserted central catheters in non-hospitalized cancer patients: 5-year results of a prospective study. Support Care Cancer 2015; 23: 403–409.

39. Ozcelik H, Gozum S and Ozer Z. Is home parenteral nutrition safe for cancer patients? Positive effects and potential catheter-related complications: a systematic review. Eur J Cancer Care 2019; 28: e13003.

40. Caccialanza R, Cereda E, Pinto C, et al. Awareness and consideration of malnutrition among oncologists: insights from an exploratory survey. Nutrition 2016; 32: 1028–1032.

41. Caccialanza R, De Lorenzo F, Gianotti L, et al. Nutritional support for cancer patients: still a neglected right? Support Care Cancer 2017; 25: 3001–3004.

42. Fujiya K, Kawamura T, Omae K, et al. Impact of malnutrition after gastrectomy for gastric cancer on long-term survival. Ann Surg Oncol 2018; 25: 974–983.
43. Ryo S, Kanda M, Ito S, et al. The controlling nutritional status score serves as a predictor of short- and long-term outcomes for patients with stage 2 or 3 gastric cancer: analysis of a multi-institutional data set. Ann Surg Oncol 2019; 26: 456–464.

44. Oh SE, Choi MG, Seo JM, et al. Prognostic significance of perioperative nutritional parameters in patients with gastric cancer. Clin Nutr 2019; 38: 870–876.

45. Luo Z, Zhou L, Balde AI, et al. Prognostic impact of preoperative prognostic nutritional index in resected advanced gastric cancer: a multicenter propensity score analysis. Eur J Surg Oncol 2019; 45: 425–431.

46. Xie FL, Wang YQ, Peng LF, et al. Beneficial effect of educational and nutritional intervention on the nutritional status and compliance of gastric cancer patients undergoing chemotherapy: a randomized trial. Nutr Cancer 2017; 69: 762–771.

47. Gavazzi C, Colatruglio S, Valoriani F, et al. Impact of home enteral nutrition in malnourished patients with upper gastrointestinal cancer: a multicentre randomised clinical trial. Eur J Cancer 2016; 64: 107–112.

48. Martos-Benítez FD, Gutiérrez-Noyola A, Soto-García A, et al. Program of gastrointestinal rehabilitation and early postoperative enteral nutrition: a prospective study. Updates Surg 2018; 70: 105–112.

49. Adiamah A, Skořepa P, Weimann A, et al. The impact of preoperative immune modulating nutrition on outcomes in patients undergoing surgery for gastrointestinal cancer: a systematic review and meta-analysis. Ann Surg 2019; 270: 247–256.

50. Qiu M, Zhou YX, Jin Y, et al. Nutrition support can bring survival benefit to high nutrition risk gastric cancer patients who received chemotherapy. Support Care Cancer 2015; 23: 1933–1939.

51. Drissi M, Cwieluch O, Lechner P, et al. Nutrition care in patients with cancer: a retrospective multicenter analysis of current practice: indications for further studies? Clin Nutr 2015; 34: 207–211.

52. Caccialanza R, Cereda E, Caraccia M, et al. Early 7-day supplemental parenteral nutrition improves body composition and muscle strength in hypophagic cancer patients at nutritional risk. Support Care Cancer. Epub ahead of print 1 November 2018. DOI:10.1007/s00520-018-4527-0.

53. De Waele E, Mattens S, Honoré PM, et al. Nutrition therapy in cachectic cancer patients. The Tight Caloric Control (TiCaCo) pilot trial. Appetite 2015; 91: 298–301.

54. Baldwin C, Spiro A, Ahern R, et al. Oral nutritional interventions in malnourished patients with cancer: a systematic review and meta-analysis. J Natl Cancer Inst 2012; 104: 371–385.

55. Senesse P, Assenat E, Schneider S, et al. Nutritional support during oncologic treatment of patients with gastrointestinal cancer: who could benefit? Cancer Treat Rev 2008; 34: 568–575.

56. Ishii T, Kawazoe A and Shitara K. Dawn of precision medicine on gastric cancer. Int J Clin Oncol. Epub ahead of print 11 April 2019. DOI:10.1007/s10147-019-01441-x.

57. Cai W, Calder PC, Cury-Boaventura MF, et al. Biological and clinical aspects of an olive oil-based lipid emulsion: a review. Nutrients 2018; 10: 7.